Eli Lilly and Company (LLY)
Lilly's experimental drug shows promise with 20.1% weight loss in mid-stage trial
Eli Lilly said on Thursday its experimental obesity drug helped patients lose as much as 20.1% of their weight in a mid-stage trial.
Eli Lilly to start late-stage trials on amylin obesity drug after it shows up to 20% weight loss in study
Eli Lilly said it will start late-stage trials on its experimental amylin obesity drug next month after it showed encouraging results in a mid-stage study. The highest dose of the weekly injection, called eloralintide, helped patients with obesity or who are overweight lose 20.1% of their body weight on average at 48 weeks.
Novo, Lilly shares rise as Trump obesity drug deal nears
Shares of obesity drugmakers Eli Lilly and Novo Nordisk rose early on Thursday in anticipation of a White House deal that would reduce prices of their blockbuster weight-loss treatments in return for expanded market access.
Here's Why Eli Lilly (LLY) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Eli Lilly (LLY) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
International Markets and Lilly (LLY): A Deep Dive for Investors
Explore how Lilly's (LLY) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Where the blockbuster weight loss drug market stands today — and what's coming next
The blockbuster weight loss drug market is entering a new chapter of growth. Eli Lilly and Novo Nordisk are both focused on fighting for market share, ramping up supply, testing new uses for their medicines and bringing the next wave of obesity drugs to patients.
Eli Lilly Has A Solid Upside Now After Its Q3 Earnings
Eli Lilly remains a top GARP opportunity, with Q3 results reinforcing its robust business growth and dominance in incretin analogs. LLY posted a 54% YoY revenue jump and a 19% EPS beat, with management raising both sales and EPS guidance for the year. A strengthened drug pipeline, particularly for orforglipron's Phase III success, de-risks future earnings and promises sustained growth beyond 2027.
Eli Lilly's obesity and diabetes treatments fuel growth and spark bidding war
The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and fueling a bidding war over another drugmaker.
Two developments Thursday–Eli Lilly's strong quarterly performance and Novo Nordisk's unsolicited $9 billion bid for a startup–show why drugmakers can't get enough of weight loss
Lilly's quarterly results Thursday, combined with Novo Nordisk's unsolicited offer for a startup, confirm the $72 billion anti-obesity market is among pharma's hottest.
Eli Lilly: The Price Upside Just Increased
Eli Lilly delivered robust Q3 2025 results and guidance for non-GAAP EPS for the second consecutive quarter. When I last checked on the stock, there was still 20% upside to LLY for the remainder of 2025. With higher guidance, this upside has risen too. Risks persist for the stock in terms of the policy environment, though. Its expected agreement with the US government is still pending, which could affect earnings.
